AI biotechnology company Generate (GENB.US) plans to raise $100 million in a US IPO. Its core asthma treatment has entered phase III clinical trials.

Focused on asthma treatment, AI biotech company Generate Biomedicines (GENB.US) submitted documents to the US Securities and Exchange Commission on Wednesday, planning to raise up to $100 million through an initial public offering. The company uses an AI drug discovery platform to develop therapies for severe asthma, with its core candidate drug already in the pivotal phase III clinical trial stage. Generate Biomedicines claims that its AI-driven Generate platform is a tightly integrated "design-build-test-learn" closed-loop system designed to generate proprietary data with therapeutic relevance and differentiated molecular solutions. The company stated that the technology's potential has been validated through three computationally designed proteins successfully entering human clinical trials, with the fastest progressing GB-0895 being an investigational long-acting anti-thymic stromal lymphopoietin monoclonal antibody currently recruiting patients for pivotal phase III clinical trials for severe asthma. Founded in 2018 and based in Somerville, Massachusetts, the company plans to list on the Nasdaq under the ticker symbol "GENB." The company had secretly submitted its IPO application on December 23, 2025. The offering is being co-managed by Goldman Sachs Group, Inc., Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald.